Non Alcoholic Steatohepatitis Nash clinical trials

Explore recruiting non alcoholic steatohepatitis nash clinical trials.

Recruiting non alcoholic steatohepatitis nash studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Alcoholic Steatohepatitis Nash trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Poland, Belgium, Austria, Hungary, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Bulgaria, Germany, Spain, Poland, Portugal, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Romania, Netherlands, Denmark, Poland, France, Ireland +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial.

Germany, France, Italy, Denmark, Spain, Poland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

Spain, Germany, France, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A research study looking at how the compound NNC0194-0499 works with birth control pills in women not able to bear children.

Austria

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Non Alcoholic Steatohepatitis Nash trials by city

Non Alcoholic Steatohepatitis Nash in Toronto Non Alcoholic Steatohepatitis Nash in Vancouver Non Alcoholic Steatohepatitis Nash in Montreal Non Alcoholic Steatohepatitis Nash in Calgary Non Alcoholic Steatohepatitis Nash in Edmonton Non Alcoholic Steatohepatitis Nash in Ottawa Non Alcoholic Steatohepatitis Nash in Winnipeg Non Alcoholic Steatohepatitis Nash in Quebec City Non Alcoholic Steatohepatitis Nash in Hamilton Non Alcoholic Steatohepatitis Nash in Kitchener Non Alcoholic Steatohepatitis Nash in London Non Alcoholic Steatohepatitis Nash in Halifax Non Alcoholic Steatohepatitis Nash in New York Non Alcoholic Steatohepatitis Nash in Los Angeles Non Alcoholic Steatohepatitis Nash in Chicago Non Alcoholic Steatohepatitis Nash in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease